Published in Drug Saf on March 25, 1991
A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol (2006) 1.21
Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm (2008) 0.92
Frequency of laboratory monitoring of chronic medications administered to nursing facility residents: results of a national Internet-based study. Consult Pharm (2008) 0.87
New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria. Antimicrob Agents Chemother (2006) 0.83
Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic beta-cells. Br J Pharmacol (1993) 0.82
State-dependent blockade of human ether-a-go-go-related gene (hERG) K(+) channels by changrolin in stably transfected HEK293 cells. Acta Pharmacol Sin (2010) 0.75
Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med (2000) 5.12
Nicotine metabolism and intake in black and white smokers. JAMA (1998) 5.03
Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med (1983) 4.80
Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr (1981) 3.72
Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control (1998) 3.47
Cotinine disposition and effects. Clin Pharmacol Ther (1983) 3.26
Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med (1986) 2.87
Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther (2011) 2.75
Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. Am J Public Health (1988) 2.63
Drug interactions with tobacco smoking. An update. Clin Pharmacokinet (1999) 2.52
Apparent underreporting of cigarette consumption among Mexican American smokers. Am J Public Health (1990) 2.47
Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther (1984) 2.43
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health (1988) 2.16
Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther (1982) 2.12
Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom (1991) 2.10
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry (2006) 1.89
Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav (2000) 1.87
Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend (1993) 1.84
Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf (2001) 1.84
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther (2009) 1.83
Is serum cotinine a better measure of cigarette smoking than self-report? Prev Med (1995) 1.82
Clonidine for smoking cessation. Cochrane Database Syst Rev (2004) 1.80
Misclassification of smoking status by self-reported cigarette consumption. Am Rev Respir Dis (1992) 1.79
Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet (1978) 1.79
Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther (2007) 1.70
Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther (1982) 1.60
Reducing tobacco addiction through tobacco product regulation. Tob Control (2004) 1.59
Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol (1997) 1.56
Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther (1997) 1.53
Toward a comprehensive long term nicotine policy. Tob Control (2005) 1.52
Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health (1999) 1.52
Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther (2011) 1.52
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med (1989) 1.48
Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. JAMA (1986) 1.45
Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther (1987) 1.45
Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine. Drug Saf (1992) 1.43
Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. Am J Respir Crit Care Med (2001) 1.42
Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol (1982) 1.41
Changes in plasma catecholamines after tonic-clonic seizures. Neurology (1984) 1.40
The use of biologic fluid samples in assessing tobacco smoke consumption. NIDA Res Monogr (1983) 1.39
Phencyclidine poisoning. JAMA (1975) 1.37
A proposal to develop meaningful labeling for cigarettes. JAMA (1994) 1.35
Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther (1985) 1.35
Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol (1997) 1.32
Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users. Clin Pharmacol Ther (1981) 1.31
Recent studies of nicotine metabolism in humans. Pharmacol Biochem Behav (1988) 1.30
Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther (2000) 1.26
Clinical pharmacology of nicotine. Annu Rev Med (1986) 1.25
Nicotine exposure among nondependent smokers. Arch Gen Psychiatry (1990) 1.24
Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther (1993) 1.20
Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest (1994) 1.16
How a cigarette is smoked determines blood nicotine levels. Clin Pharmacol Ther (1983) 1.16
Environmental and drug-induced hyperthermia. Pathophysiology, recognition, and management. Emerg Med Clin North Am (1984) 1.16
Workshop on problem-based learning as a method for teaching clinical pharmacology and therapeutics in medical school. J Clin Pharmacol (1992) 1.15
Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis. Clin Nephrol (1979) 1.13
Nicotine elimination and tolerance in non-dependent cigarette smokers. Psychopharmacology (Berl) (1992) 1.12
Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther (1975) 1.12
Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. Clin Pharmacol Ther (1984) 1.11
Nicotine and carbon monoxide intake from high- and low-yield cigarettes. Clin Pharmacol Ther (1984) 1.10
Cardiopulmonary catastrophes in drug-overdosed patients. Med Clin North Am (1979) 1.10
Clinical pharmacology of nicotine. Clin Dermatol (1998) 1.09
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther (2007) 1.06
Disposition kinetics and effects of intravenous nicotine. Clin Pharmacol Ther (1980) 1.06
Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users. J Chromatogr (1993) 1.06
Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res (1989) 1.06
Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther (1977) 1.04
Disposition kinetics and effects of menthol. Clin Pharmacol Ther (1999) 1.03
Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. Chem Res Toxicol (1992) 1.03
Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther (1988) 1.03
Treating tobacco addiction--nicotine or no nicotine? N Engl J Med (1997) 1.02
Blood cotinine levels as indicators of smoking treatment outcome. Clin Pharmacol Ther (1984) 1.02
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther (2012) 1.02
Pharmacokinetics of haemoperfusion for drug overdose. Clin Pharmacokinet (1980) 1.01
The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Drugs Aging (1996) 1.00
Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther (2000) 1.00
Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther (1979) 1.00
Tricyclic antidepressant poisoning. Management of arrhythmias. Med Toxicol (1987) 1.00
Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. J Pharm Biomed Anal (2000) 0.98
Influence of race, tobacco use, and caffeine use on the relation between blood pressure and blood lead concentration. Am J Epidemiol (1990) 0.98
Cardiovascular effects of carbon monoxide and cigarette smoking. J Am Coll Cardiol (2001) 0.97
A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology (Berl) (1994) 0.96
Individualizing medical treatment for tobacco dependence. Eur Respir J (1996) 0.96
Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther (1998) 0.96
Effect of disulfiram on adrenergic function. Clin Pharmacol Ther (1979) 0.94
Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther (1985) 0.94
Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine. Eur J Clin Pharmacol (2000) 0.93
Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. Clin Pharmacol Ther (1987) 0.92
Saliva cotinine levels as a function of collection method. Addiction (1997) 0.92
Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther (1990) 0.92
Determination of the nicotine metabolite trans-3'-hydroxycotinine in urine of smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J Chromatogr (1992) 0.92
Seizures associated with poisoning and drug overdose. Am J Emerg Med (1994) 0.91
Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide. Chem Res Toxicol (1994) 0.91
The effect of cigarette smoking on penile erection. J Urol (1987) 0.91
Nicotine gum and behavioral treatment: a placebo controlled trial. J Consult Clin Psychol (1987) 0.91
Seizures associated with poisoning and drug overdose. Am J Emerg Med (1993) 0.90
Nicotine content of the eclipse nicotine delivery device. Am J Public Health (1997) 0.90
Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. Br J Clin Pharmacol (2005) 0.90
Absorption rate of methylxanthines following capsules, cola and chocolate. Eur J Clin Pharmacol (1996) 0.90
Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet (1977) 0.90